Ovid Therapeutics Inc. is a biopharmaceutical company focused on improving the lives of people with epilepsies and brain conditions with seizure symptoms. It advances a pipeline of novel, targeted small molecule candidates that modulate factors involved in neuronal hyperexcitability. Key developments include OV888 (GV101), a ROCK2 inhibitor for cerebral cavernous malformations; OV329, a GABA-aminotransferase inhibitor for treatment-resistant seizures; and OV350, a KCC2 transporter activator for epilepsies and psychiatric conditions. It also develops soticlestat, a cholesterol 24-hydroxylase inhibitor for Dravet and Lennox-Gastaut syndromes. The OVID YTD return is shown above.
The YTD Return on the OVID YTD return page and across the coverage universe of our site,
is a measure of the total return for a given investment year-to-date for the current calendar year
(up to the end of prior trading session). Arguably, choosing the current calendar year for a measurement
period is on the one hand completely arbitrary, but on the other hand a year-to-date look can be extremely
useful in the context of our country's tax system which taxes gains and income on a calendar year basis.
Thus, researching Year-To-Date Returns is good practice for investors — whether OVID YTD return or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's YTD return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the OVID YTD return calculation (with any dividends reinvested as applicable), and to provide a
coverage universe of many stocks and ETFs to be able to compare YTD returns.
|